Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724583 | 0.83 | DBH (0.37) | DBHMAOAALDH1A1ALOX15HSD17B10 | |
| SCHEMBL8018526 | 0.74 | TSHR (0.38) | ALDH1A1TDP1LMNARECQLTSHR | |
| SCHEMBL7487292 | 0.74 | CYP3A4 (0.33) | ALDH1A1ALOX15HSD17B10TDP1HPGD | |
| SCHEMBL31748052 | 0.74 | RPS6KA3 (0.37) | ALDH1A1TDP1HPGDCA2CA1 | |
| SCHEMBL317892 | 0.70 | MAPT (0.40) | MAOAALDH1A1ALOX15TDP1LMNA | |
| SCHEMBL5492262 | 0.69 | ACP3 (0.45) | SMN1; SMN2 | |
| SCHEMBL8194088 | 0.68 | SMN1; SMN2 (0.46) | ALDH1A1HSD17B10TDP1HPGDRECQL | |
| SCHEMBL31619158 | 0.68 | DBH (0.35) | DBHMAOAALDH1A1ALOX15HSD17B10 | |
| SCHEMBL21359837 | 0.68 | MAPT (0.38) | MAOAALDH1A1ALOX15TDP1LMNA | |
| Hydrochloric Acid SCHEMBL2948518 | 0.68 | MAPT (0.38) | MAOAALDH1A1ALOX15TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6096743-A | 1,2,3,4-tetrahydroquinoxalinedione derivative | YAMANOUCHI PHARMACEUTICALS CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | disclosed |
| EP-0876357-A1 | NEW QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-11 | — | — | EP | disclosed |
| EP-0784054-A1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997019066-A1 | NEW QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | DBH 2431/4885MAOA 4460/4885ALDH1A1 3961/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | DBH 858/4885MAOA 3634/4885ALDH1A1 2518/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | DBH 2331/4885MAOA 4476/4885ALDH1A1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.